GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK plc reports that, acting through BNP Paribas, it bought back 470,000 ordinary shares of 31¼ pence each on 19 February 2026. The purchases were made at prices between 2,217.00p and 2,264.00p per share, with a volume-weighted average price of 2,243.09p.
The shares will be held as treasury shares under GSK’s existing buyback programme, pursuant to a non-discretionary agreement with the broker announced on 17 February 2026. Since that date, GSK has repurchased 1,300,000 shares. After this transaction, it holds 241,191,094 shares in treasury and has 4,074,951,475 shares in issue, which equals 4,074,951,475 voting rights. Treasury shares represent 5.92% of voting rights under the Disclosure Guidance and Transparency Rules.
GSK plc reported a transaction involving Chief Scientific Officer Tony Wood related to its Deferred Investment Award Programme. On 18 February 2026, 25% of an award granted on 18 February 2021 vested. In connection with this vesting, Wood will receive a cash payment of £204,048.58, before tax, corresponding to 8,996.851 notional ordinary shares of 31¼ pence each, valued at £22.68 per share. This is recorded as a single transaction under GSK’s remuneration arrangements for senior management.
GSK plc reports that, acting through BNP Paribas, it repurchased 410,000 ordinary shares on 18 February 2026 as part of its existing share buyback programme. The shares, with a volume-weighted average price of 2,268.77p, will be held as treasury shares.
Since 17 February 2026, GSK has bought back a total of 830,000 ordinary shares. After these transactions, it holds 240,721,094 shares in treasury and has 4,075,421,475 ordinary shares in issue, which is also the total number of voting rights.
The company states that treasury shares now represent 5.91% of the voting rights. Detailed schedules list the prices and volumes of trades executed on the London Stock Exchange and Cboe Europe venues as part of this programme.
GSK plc repurchased 420,000 ordinary shares of 31¼ pence each on 17 February 2026, acting through BNP Paribas under a non-discretionary agreement as part of its existing share buyback programme. The shares were bought at prices between 2,189.00p and 2,259.00p, with a volume-weighted average price of 2,231.39p.
The repurchased shares will be held as treasury shares. After this transaction, GSK holds 240,311,094 ordinary shares in treasury and has 4,075,831,475 ordinary shares in issue excluding treasury shares, which is also the total number of voting rights. Treasury shares represent 5.90% of voting rights attributable to ordinary shares.
GSK plc reported a management share transaction involving President Maya Martinez-Davis. On February 13, 2026, performance share awards granted in 2020 under GSK’s 2017 Performance Share Plan vested, delivering 10,836.957 American Depositary Shares (ADS) at a price of $0.00 to the executive.
On the same date, 4,009.778 ADS were sold on the New York Stock Exchange at a price of $58.8509 per ADS to meet tax liabilities arising from the vesting. The remaining ADS from the award vesting continue to be held by the executive. These transactions reflect routine equity-based compensation and related tax settlement for a senior leader.
GSK plc reported that awards granted in 2023 under its 2017 Performance Share Plan for senior leaders vested at 82% of maximum, with 18% lapsing, after a three-year performance period to 31 December 2025. Vesting was driven by several business measures. Total sales over the period reached £99.03bn, above the £94.58bn level required for full vesting on that metric, while total profit was £30.22bn, above the £29.43bn 100% vesting hurdle. Total shareholder return ranked fifth in a peer group of 10 global pharmaceutical companies. Pipeline progress and responsible business environmental targets also achieved maximum vesting levels. On 13 February 2026, multiple PDMRs and one person closely associated received vested Ordinary Shares or ADS at no cost and sold portions at market prices, mainly around £21.6002 per Ordinary Share and $58.8509 per ADS, solely to meet tax liabilities.
GSK plc is launching the fourth tranche of its previously announced £2 billion share buyback programme. This new tranche allows buybacks of up to £0.45 billion of ordinary shares, with purchases expected between 17 February 2026 and 24 April 2026.
GSK has entered a non-discretionary agreement with BNP Paribas S.A., which will independently execute trades on specified European venues. Shares repurchased in this tranche will be held as treasury shares. The programme is intended to return excess capital, reduce share capital, and is expected to enhance earnings per share.
The fourth tranche will be conducted within GSK’s existing authority to repurchase up to 413,957,879 ordinary shares granted at its 2025 Annual General Meeting, and will comply with applicable UK and EU-derived market regulations. No repurchases will be made in the United States or in respect of American Depositary Receipts.
GSK reports that the European Commission has approved Exdensur (depemokimab) for two uses: add-on maintenance treatment for severe asthma with type 2 inflammation in patients 12 and older, and add-on therapy for adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP).
Exdensur is described as the first ultra-long-acting biologic in the EU for respiratory diseases, given just twice a year. In phase III SWIFT trials, adding depemokimab to standard care cut annualised severe asthma exacerbations by 58% and 48% in SWIFT-1 and SWIFT-2, and a pooled analysis showed a 72% reduction in clinically significant exacerbations needing hospital or emergency visits.
In ANCHOR phase III trials for CRSwNP, depemokimab improved nasal polyp scores and nasal obstruction ratings versus placebo, while overall side effect rates and severity were similar to placebo. Exdensur already has approvals in the US, UK and Japan, and depemokimab is being studied in additional type 2 inflammation conditions and COPD.
GSK plc has granted 2026 performance share plan awards to senior executives and set detailed performance measures for vesting. The conditional share awards run over a three-year period from 1 January 2026 to 31 December 2028 and are granted under the GlaxoSmithKline 2017 Performance Share Plan.
Each award’s vesting depends on five measures: total sales growth, core operating profit growth and pipeline sustainability at 17.5% each, a responsible business composite scorecard at 7.5%, and relative total shareholder return (TSR) at 40%. Dividends accrue during the period but only vest if the underlying awards vest.
For the CEO and other PDMRs, threshold vesting levels differ for some metrics, and awards that do not meet performance conditions will lapse. Executive Directors also face an additional two-year holding period after normal vesting, extending their total time horizon to five years.
GSK plc reported that senior leaders received deferred share bonuses for 2025 performance under its 2017 Deferred Annual Bonus Plan. On 12 February 2026, awards were granted mainly as Ordinary Shares priced at £21.50 and, for one executive, as ADS priced at $58.49.
The plan requires Executive Directors and Executive Committee members to defer a portion of their annual bonus into shares for three years. Examples include CEO Luke Miels receiving 27,962 Ordinary Shares and CFO Julie Brown receiving 55,178 Ordinary Shares, with additional awards to other committee members.